EMD - emerin Gene
Species: Oryctolagus cuniculus
Gene Type: protein coding
Gene ID: 100328755
EMD Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001171372.1 | NP_001164843.1 | emerin |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
emerin |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(8)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-14721 | Tepotinib | 99.94% | Yes | |
| HY-14262 | Vilazodone | 99.73% | Unkown | |
| HY-14261 | Vilazodone Hydrochloride | 99.94% | Unkown | |
| HY-70057 | Safinamide | Inhibitor | 99.86% | Yes |
| HY-14771A | Imeglimin hydrochloride | 99.98% | Unkown | |
| HY-70057A | Safinamide mesylate | Inhibitor | 99.07% | Yes |
| HY-14771 | Imeglimin | 99.10% | Unkown | |
| HY-14721A | Tepotinib hydrochloride | / | Unkown |
Clinical Phase
Bioactive Molecules
(17)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-16141 | Cilengitide | 99.91% | Phase 3 | |
| HY-100820 | Sarizotan | Agonist | 98.23% | Phase 3 |
| HY-107384A | Asimadoline hydrochloride | Agonist | 99.57% | Phase 3 |
| HY-107384 | Asimadoline | Agonist | 99.36% | Phase 3 |
| HY-100820A | Sarizotan hydrochloride | Agonist | / | Phase 3 |
| HY-100820B | Sarizotan dihydrochloride | Agonist | / | Phase 3 |
| HY-106246 | Pruvanserin | Antagonist | 99.54% | Phase 2 |
| HY-103115 | Pruvanserin hydrochloride | Antagonist | / | Phase 2 |
| HY-106100 | Roxindole | / | Phase 2 | |
| HY-133931 | Bimakalim | / | Phase 2 | |
| HY-19273 | Rimeporide | Inhibitor | 98.63% | Phase 1 |
| HY-15000 | EMD534085 | Inhibitor | 99.55% | Phase 1 |
| HY-103410 | Carmoxirole hydrochloride | Agonist | 99.82% | Phase 1 |
| HY-106844 | EMD 53998 | Inhibitor | 99.59% | Phase 1 |
| HY-105112 | Carmoxirole | Agonist | / | Phase 1 |
| HY-123356 | EMD-503982 | Inhibitor | / | Phase 1 |
| HY-19273A | Rimeporide hydrochloride | Inhibitor | / | Phase 1 |
Bioactive MoleculesInhibitory Antibodies
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P991214 | Tucotuzumab celmoleukin | 98.797% | Phase 3 | |
| HY-P9969 | Matuzumab | 98.12% | Phase 2 | |
| HY-P99183 | Abituzumab | Inhibitor | 99.38% | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(42)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-15193 | EMD638683 | 99.94% | Unkown | |
| HY-16143 | Cilengitide TFA | 99.92% | Yes | |
| HY-P0322 | GRGDSPK | Inhibitor | 98.55% | Unkown |
| HY-106844A | (+)-EMD 57033 | 99.72% | Unkown | |
| HY-101473 | EMD527040 | Inhibitor | 99.88% | Unkown |
| HY-106100A | Roxindole hydrochloride | 99.48% | Unkown | |
| HY-106150B | Eniporide hydrochloride | Inhibitor | 99.49% | Unkown |
| HY-14203 | (R)-Safinamide | Inhibitor | 99.89% | Unkown |
| HY-107030 | Nitrefazole | 99.44% | Unkown | |
| HY-136280 | Panamesine | 99.54% | Unkown | |
| HY-170410 | EMD-95885 | Antagonist | 98.74% | Unkown |
| HY-15193B | EMD638683 (S-Form) | Inhibitor | 99.95% | Unkown |
| HY-103130 | EMD386088 | Agonist | 99.06% | Unkown |
| HY-15193A | EMD638683 (R-Form) | Inhibitor | 99.86% | Unkown |
| HY-19134 | EMD 56551 | Agonist | / | Unkown |
| HY-70057S1 | Safinamide-d4-1 | Inhibitor | 98.90% | Unkown |
| HY-19273R | Rimeporide (Standard) | Inhibitor | 98.11% | Unkown |
| HY-101473A | EMD527040 hydrochloride | Antagonist | / | Unkown |
| HY-103130A | EMD 386088 free base | Agonist | / | Unkown |
| HY-103247 | EMD 66684 | Antagonist | / | Unkown |
| HY-103247B | EMD-66684 potassium salt | Antagonist | / | Unkown |
| HY-105539 | EMD 86006 | Inhibitor | / | Unkown |
| HY-106150A | Eniporide mesylate | Inhibitor | / | Unkown |
| HY-10777 | EMD 495235 | Inhibitor | / | Unkown |
| HY-114987 | EMD 21657 | Modulator | / | Unkown |
| HY-114990 | EMD 57439 | Inhibitor | / | Unkown |
| HY-14262S1 | Vilazodone-d8 hydrochloride | / | Unkown | |
| HY-169827 | EMD-132338 | Antagonist | / | Unkown |
| HY-175878 | EMD-C02602 | Modulator | / | Unkown |
| HY-A0300 | Cyclopeptide-5 | Antagonist | / | Unkown |
| HY-P0322A | GRGDSPK TFA | Inhibitor | / | Unkown |
| HY-P2075 | EMD 55068 | Antagonist | / | Unkown |
| HY-RS04345 | EMD Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-106150 | Eniporide | Inhibitor | / | Unkown |
| HY-106472 | Tioxaprofen | Inhibitor | / | Unkown |
| HY-129714 | EMD 52297 | Inhibitor | / | Unkown |
| HY-14771S | Imeglimin-d3 | / | Unkown | |
| HY-164394 | EMD 1204831 | Inhibitor | / | Unkown |
| HY-70057S4 | Safinamide-d5 | Inhibitor | / | Unkown |
| HY-RS17358 | Emd Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23812 | Emd Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W705589 | Rimeporide-15N3 hydrochloride | Inhibitor | / | Unkown |